Clinical Trials Logo

Clinical Trial Summary

TIBOLA (TIck-BOrne LymphAdenopathy) is a tick-borne disease. The pathogen is most often rickettsia (R. slovaca or R. raoultii), but other strict intracellular bacteria have been described (Francisella tularensis, Coxiella burnetii, Bartonella hensenlae). Transmitted by ticks (Dermacentor), it is characterized by an inoculation eschar at the tick bite site, accompanied by painful loco-regional lymphadenopathy. It is most often a benign pathology, which can nevertheless leave sequellar alopecia or persistent asthenia. In spring 2021, an impression of increased cases was reported by clinicians in Eastern France. The study aims to clarify the clinical-biological presentation and the evolution of the number of cases of TIBOLA in this region between 2016 and 2021. At the same time, entomologists have noted an upsurge in this tick in certain biotopes in recent years.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05458245
Study type Observational
Source Central Hospital, Nancy, France
Contact
Status Recruiting
Phase
Start date June 1, 2022
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT00326534 - Rickettsial Genesis to Sarcoidosis in Denmark N/A